Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome
Status:
Completed
Trial end date:
2019-02-12
Target enrollment:
Participant gender:
Summary
BACKGROUND: Currently, there is no proven pharmacologic treatment for patients with the acute
respiratory distress syndrome (ARDS). Great interest remains in the use of corticosteroids
for the salvage of patients with severe acute lung injury in the early phase of their disease
process, a situation that that has not been evaluated in most published trials. Dexamethasone
has never been evaluated in ARDS in a randomized controlled fashion.
HYPOTHESIS AND OBJECTIVES: The investigators hypothesize that adjunctive treatment with
intravenous dexamethasone of patients with established ARDS might change the pulmonary and
systemic inflammatory response and thereby will increase the number of ventilator-free days
and will decrease the extremely high overall mortality. Our goal is to examine the effects of
dexamethasone on length of duration of mechanical ventilation (assessed by number of
ventilator-free days) and on mortality, in patients admitted into a network of Spanish
intensive care units (ICUs) who still meet ARDS criteria at 24 hours after ARDS onset.
Phase:
Phase 4
Details
Lead Sponsor:
Dr. Negrin University Hospital
Collaborators:
Asociación Científica Pulmón y Ventilación Mecánica Fundación Mutua Madrileña